Topics

High-grade gliomas | Treatment | Case reports | Dabrafenib

Home > Publications > Topics > High-grade gliomas > Treatment > Case reports > Dabrafenib

Kawaguchi Y, Watanabe Y, Miyakita Y, Ohno M, Ogawa C, Takahashi M, Yanagisawa S, Mukai T, Igaki H, Sugino H, Yoshida A, Narita Y.
Successful treatment of pediatric patients with high-grade gliomas featuring leptomeningeal metastases by targeting BRAF V600E mutations with dabrafenib plus trametinib: two illustrative cases.
Int Cancer Conf J. 2024 Apr 10;13(3):256-262. doi: 10.1007/s13691-024-00674-6. PMID: 38962052. Case report˰ ˍ

Castelli B, Tellini M, Guidi M, Di Nicola M, Giunti L, Buccoliero AM, Censullo ML, Iacono A, Desideri I, Genitori L, Sardi I, Fonte C.
Case report: complete long-lasting response to multimodal third line treatment with neurosurgical resection, carmustine wafer implantation and dabrafenib plus trametinib in a BRAFV600E mutated high-grade glioma.
Front Oncol. 2024 May 7;14:1359093. doi: 10.3389/fonc.2024.1359093. PMID: 38774414. Case report. ˍ

Kawaguchi Y, Hana T, Hasegawa H, Murakami C, Higashi M, Hanakita S.
Rapid response to BRAF/MEK inhibitor therapy within 2 weeks for high-grade glioma with leptomeningeal metastasis: illustrative case.
J Neurosurg Case Lessons. 2025 Jul 7;10(1):CASE25247. doi: 10.3171/CASE25247. PMID: 40623326. Case report. ˍ